Association between body mass index and mortality in patients with glioblastoma mutliforme
- 154 Downloads
To examine the association between obesity and survival in patients with glioblastoma mutliforme (GBM)
Using a prospective design, 1,259 patients with previously untreated GBM were recruited between 1991 and 2008. Height and weight were self-reported or abstracted from medical records at study entry and used to calculate body mass index (BMI) [weight (kg)/[height (m)]2. Cox proportional models were used to estimate the risk of death associated with BMI as a continuous variable or categorized using established criteria (normal weight, 18.5–24.9 kg/m2; overweight, 25.0–29.9 kg/m2; obese, ≥30.0 kg/m2).
Median follow-up was 40 months, and 1,069 (85%) deaths were observed during this period. For all patients, minimal adjusted analyses indicated no significant association between BMI treated as a continuous variable and survival. Compared with patients with a BMI 18.5–24.9 kg/m2, the minimally adjusted HR for overall survival was 1.08 (95% CI, 0.94–1.24) for a BMI 25–29.9 kg/m2 and 1.08 (95% CI, 0.91–28) for a BMI ≥30.0 kg/m2. After additional adjustment for adjuvant therapy, the HR for those with a BMI of 25.0–29.9 kg/m2 was 1.14 (95% CI, 0.99–1.32) and 1.09 (95% CI, 0.91–1.30) for those with a BMI ≥30.0 kg/m2. No significant interactions were revealed for BMI and any demographic variables.
BMI was not associated with survival in newly diagnosed and previously untreated patients with GBM. Further research investigating the prognostic significance of alternative, quantitative measures of body habitus, and functional performance are required.
KeywordsEpidemiology Glioblastoma Survival Prognosis Body weight Energy balance
The study was funded by NIH grants CA108786-04, CA52689, CA097257, Robert J. and Helen H. Glaser Family Foundation and Elvira Olsen Family Fund. LWJ is supported by NIH CA143254, CA142566, CA138634, CA133895, CA125458 and funds from George and Susan Beischer.
- 2.Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMedGoogle Scholar
- 3.Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563–2569CrossRefPubMedGoogle Scholar
- 4.Affronti ML, Heery CR, Herndon JE II, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS (2009) Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 115:3501–3511CrossRefPubMedGoogle Scholar
- 5.Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE.3. Lancet Oncol 9:29–38CrossRefPubMedGoogle Scholar
- 9.Li CI, Daling JR, Porter PL, Tang MT, Malone KE (2009) Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 27:5312–5318CrossRefPubMedGoogle Scholar
- 10.de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjold B, Gutierez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M (2010) The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 119:145–153Google Scholar
- 11.Chen X, Lu W, Zheng W, Gu K, Chen Z, Zheng Y, Shu XO (2010) Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat 823–833Google Scholar
- 14.Jayachandran J, Banez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ (2009) Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 115:5263–5271CrossRefPubMedGoogle Scholar
- 19.Il’yasova D, Marcello JE, McCoy L, Rice T, Wrensch M (2009) Total dietary antioxidant index and survival in patients with glioblastoma multiforme. Cancer Causes Control 20(8):1255–1260 Google Scholar
- 21.Jones LW, Friedman AH, West MJ, Mabe SK, Fraser J, Kraus WE, Friedman HS, Tresch MI, Major N, Reardon DA (2010) Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. Cancer 116:695–704Google Scholar
- 22.Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann OncolGoogle Scholar
- 23.Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE (2010) Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results From a placebo-controlled study. J Clin Oncol 1054–1060Google Scholar
- 25.Jones LW, Mourtzakis M, Peters KB, Friedman AH, West MJ, Mabe S, Kraus WE, friedman HS, Reardon DA (2010) Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma. Oncologist 15:636–647Google Scholar